Related Experiment Video
Updated: Apr 28, 2026
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Rosiglitazone amplifies the sensitivity of docetaxel and reduces the expression of CD44v6
Fahe Ji1, Dongchu Ma1, Zhaozhe Liu1
1Department of Oncology, The General Hospital of Shenyang Military Command, Shenyang, Liaoning 110840, P.R. China.
Abstract:
Breast cancer seriously impairs physical and mental health in females. Currently, with further investigation into drugs, a number of new pharmacological effects have been found that offer new methods for clinical application in the treatment of breast cancer. As a widely used antidiabetic drug, rosiglitazone (Ros) has become well known for its anticancer effects, mediated by the activation of peroxisome proliferator-activated receptor γ and downregulated expression of the associated invasion gene. The objective of the present study was to investigate the combination of Ros and docetaxel (DOC) and whether DOC has any effect on breast cancer cell lines. The results showed that the combination of Ros and DOC may cooperate to increase anti-growth efficacy. The additive inhibitory effects on cell proliferation were sequence-dependent and are not likely to be associated with cell cycle arrest. This suggested that the target activation of associated factors of the signaling pathway by Ros may be a compelling ally in cancer treatment. In addition, evidence was provided for a convergence of Ros and DOC to induce the reduced expression of CD44v6. Future studies are required to confirm which associated gene of Ros is significant in blocking the signaling pathway.
Insights
Rosiglitazone (Ros) and docetaxel (DOC) combination therapy shows enhanced anti-breast cancer efficacy. This drug combination may offer new treatment strategies by inhibiting cancer cell proliferation.
Area of Science:
- Oncology
- Pharmacology
Background:
- Breast cancer significantly impacts female physical and mental health.
- Rosiglitazone (Ros), an antidiabetic drug, exhibits anticancer properties via peroxisome proliferator-activated receptor γ activation.
- This study explores the synergistic effects of Rosiglitazone and docetaxel (DOC) in breast cancer treatment.
Purpose of the Study:
- To investigate the combined efficacy of Rosiglitazone and docetaxel on breast cancer cell lines.
- To determine if docetaxel influences breast cancer cell lines.
- To explore potential synergistic or additive effects of the drug combination.
Main Methods:
- Investigated the effects of Rosiglitazone and docetaxel on breast cancer cell lines.
- Assessed the combination's impact on cell proliferation and growth.
- Analyzed the sequence-dependent effects of drug administration.
Main Results:
- The combination of Rosiglitazone and docetaxel demonstrated cooperative anti-growth effects.
- Inhibitory effects on cell proliferation were sequence-dependent and not linked to cell cycle arrest.
- Evidence suggests a convergence of Rosiglitazone and docetaxel in reducing CD44v6 expression.
Conclusions:
- The combination of Rosiglitazone and docetaxel shows potential for enhanced anti-breast cancer efficacy.
- Rosiglitazone's activation of signaling pathways may be beneficial in cancer treatment.
- Further research is needed to identify specific genes involved in Rosiglitazone's pathway blockade.
More Related Videos
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
06:08Author Spotlight: Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase